Research Perspective|Volume 15, Issue 14|pp 6632—6640

Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?

Mikhail V. Blagosklonny¹

¹Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

Received: May 2, 2023Accepted: July 17, 2023Published: July 20, 2023

https://doi.org/10.18632/aging.204920

Copyright: © 2023 Blagosklonny. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Both individuals taking rapamycin, an anti-aging drug, and those not taking it will ultimately succumb to age-related diseases. However, the former, if administered disease-oriented dosages for a long time, may experience a delayed onset of such diseases and live longer. The goal is to delay a particular disease that is expected to be life-limiting in a particular person. Age-related diseases, quasi-programmed during development, progress at varying rates in different individuals. Rapamycin is a prophylactic anti-aging drug that decelerates early development of age-related diseases. I further discuss hyperfunction theory of quasi-programmed diseases, which challenges the need for the traditional concept of aging itself.